Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Compound in-situ gel long-acting injection for treating chronic hepatitis and preparation method thereof

A gel injection and in-situ gel technology, applied in the field of medicine, can solve the problems of patients forgetting to take medicine, affecting curative effect, and long treatment cycle

Active Publication Date: 2014-01-08
HYBIO PHARMA
View PDF5 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] However, on the market, both interferon and thymofasin are only common injections, and the treatment cycle is long (more than one year on average), requiring frequent and long-term administration. Generally, interferon is injected once every other day and thymofasin is subcutaneously injected twice a week. , it is easy to bring compliance and forgetting medication problems to patients, and ultimately affect the curative effect, so it is necessary and feasible to develop a new compound long-acting injection containing interferon and thymus method for chronic hepatitis B, currently Interferon and thymofaxin compound long-acting injection has not been reported yet

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Compound in-situ gel long-acting injection for treating chronic hepatitis and preparation method thereof
  • Compound in-situ gel long-acting injection for treating chronic hepatitis and preparation method thereof
  • Compound in-situ gel long-acting injection for treating chronic hepatitis and preparation method thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0064] Weigh 15 mg of interferon a-2b and dissolve it in sterile water for injection, add 35 mg of zinc hydroxide that has been micronized and sterilized, and vortex and mix for 10 minutes to form 1 g of zinc salt interferon a-2b solution.

[0065] Weigh 2.6g PLGA (weight-average molecular weight 10000, intrinsic viscosity 0.10dl / g-0.20dl / g, LA:GA=75:25), 0.9g poloxamer 407 and 18g NMP, mix well, and prepare a polymer Then add 0.30g of Thymusfaxin raw material drug, ultrasonically dissolve, add 1g of zinc salt interferon a-2b solution after complete dissolution, heat at constant temperature and stir at high speed (temperature 30°C, 10000rpm) for 5min to form drug-loaded particles The sol system is sterilized by electron beams to obtain the compound long-acting in-situ gel injection. The drug loading amount of interferon was detected by HPLC to be 0.37%, and the encapsulation efficiency was 95%. The drug loading of thymus method was 7.18%, and the encapsulation rate was 92%. ...

Embodiment 2

[0069] Weigh 20 mg of interferon a-2a and dissolve it in sterile water for injection, add 55 mg of zinc chloride after micronization and sterilization, and vortex and mix for 10 minutes to form 1 g of zinc salt interferon a-2a solution.

[0070] Weigh 4.0g PLGA (weight average molecular weight 15000, intrinsic viscosity 0.10dl / g-0.25dl / g, LA:GA=65:35), 2.0g methylcellulose and 45g ethyl lactate, mix well, and prepare Polymer solution, then add 0.80g of Thymofaxin API, ultrasonically dissolve, add 1g of zinc salt interferon a-2a solution after complete dissolution, heat at constant temperature and stir at high speed (temperature 30°C, 10000rpm) for 7min, to form a carrier containing particles The drug sol system is sterilized by electron beams to obtain the compound long-acting in-situ gel injection. The drug loading amount of interferon was detected by HPLC to be 0.33%, and the encapsulation efficiency was 97%. The drug loading capacity of thymus method was 12.53%, and the en...

Embodiment 3

[0074] Weigh 25 mg of interferon a-1b and dissolve it in sterile water for injection, add 55 mg of magnesium hydroxide that has been micronized and sterilized, and vortex and mix for 10 minutes to form a solution of 1 g of magnesium salt interferon a-1b.

[0075] Weigh 3.75g PLA (weight-average molecular weight 15000, intrinsic viscosity 0.10dl / g-0.25dl / g), 3.75g Carbomer 934 and 35g acetone, mix well, and prepare polymer solution, then add new thymus method raw material 0.75g of drug, ultrasonically dissolved, after complete dissolution, add 1g of magnesium salt interferon a-1b solution, heat at constant temperature and high-speed stirring (temperature 30°C, 10000rpm) for 5min, to form a drug-loaded sol system containing particles, and sterilize with electron beams , to obtain compound long-acting in situ gel injection. The drug loading amount of interferon was detected by HPLC to be 0.28%, and the encapsulation efficiency was 98%. The drug loading of thymus method was 12.44...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
molecular weightaaaaaaaaaa
encapsulation rateaaaaaaaaaa
encapsulation rateaaaaaaaaaa
Login to View More

Abstract

The invention relates to the technical field of medicine, and discloses a compound in-situ gel long-acting injection for treating chronic hepatitis and a preparation method thereof. The compound in-situ gel long-acting injection for treating chronic hepatitis, disclosed by the invention, is prepared from 5-24 parts of zinc salt interferon a or magnesium salt interferon a, 150-800 parts of thymalfasin, 1800-12000 parts of in-situ gel materials, and 8000-100000 parts of solvent. The compound in-situ gel long-acting injection disclosed by the invention is prepared from the thymalfasin, the interferons and proper in-situ gel materials. Thus, the administration frequency is reduced; the medicine effect can be stably and lastingly released for a long period of time; the compound in-situ gel long-acting injection is free of obvious toxic and side effects, and high in medicine concentration and encapsulation efficiency; the product quality is superior to the specified standard; the compound in-situ gel long-acting injection is suitable for popularization and application in treatment of the chronic hepatitis.

Description

technical field [0001] The invention relates to the technical field of medicine, in particular to a compound long-acting in-situ gel injection for treating chronic hepatitis B and a preparation method thereof. Background technique [0002] Hepatitis B virus (HBV) infection is one of the most common viral infections in humans. There are about 300 million chronic HBV infected people in the world, most of whom are in Asia. Chronic HBV carriers account for about 10% to 15% of the Chinese population. Liver cirrhosis and hepatocellular carcinoma account for 2% and 1% of chronic hepatitis B (CHB) patients each year, respectively, and this figure is still on the rise. 90% of patients with hepatitis B can go to the hospital for treatment, and on average about 40% of patients relapse and are admitted to hospital for treatment. [0003] A large number of studies have proved that interferon is currently recognized as an effective drug for the treatment of viral hepatitis at home and ab...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K9/06A61K38/21A61K38/16A61P31/20
Inventor 颜携国陶安进马亚平袁建成
Owner HYBIO PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com